Let’s hope the terrorists aren’t a year ahead
VaxGen is at least a year behind schedule in developing a new anthrax vaccine. From the Washington Post:
Until the full stockpile of 75 million doses is ready, the United States would depend on antibiotics to treat a large-scale anthrax attack, a strategy that terrorists could overcome by creating antibiotic-resistant anthrax.
The Post takes an unwarranted dig at VaxGen and smaller companies in general:
The difficulties appear to confirm predictions on Capitol Hill two years ago that a small company like VaxGen wouldn’t be able to meet an aggressive schedule for stockpiling millions of doses of a new anthrax vaccine.
Maybe a lumbering industry giant would be faster?March 17, 2006